Comparative Pharmacology
Head-to-head clinical analysis: KETAMINE HYDROCHLORIDE versus PROPOFOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETAMINE HYDROCHLORIDE versus PROPOFOL.
KETAMINE HYDROCHLORIDE vs PROPOFOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
None Documented
None Documented
Clinical Note
moderatePropofol + Torasemide
"The risk or severity of adverse effects can be increased when Propofol is combined with Torasemide."
Clinical Note
moderatePropofol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Propofol is combined with Etacrynic acid."
Clinical Note
moderatePropofol + Furosemide
"The risk or severity of adverse effects can be increased when Propofol is combined with Furosemide."
Clinical Note
moderatePropofol + Bumetanide
Terminal elimination half-life of ketamine is 2.5–3 hours; norketamine half-life is approximately 4 hours. Context: Prolonged elimination may occur with hepatic impairment or high-dose infusions.
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Ketamine is primarily metabolized in the liver via N-demethylation to norketamine. Renal excretion accounts for approximately 90% of the dose, with 4% as unchanged drug, 16% as norketamine, and the remainder as conjugated metabolites. Fecal excretion is minimal (<5%).
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Category C
Category A/B
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Propofol is combined with Bumetanide."